Drug Discovery World

DECEMBER 19, 2022

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma. . The post Partnership to co-develop cell therapy for multiple myeloma appeared first on Drug Discovery World (DDW).

Development 52

Development Engineer Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Figures from the Amercian Cancer Society 1 state that “a little over 1.9

Development 65

Development Research Drugs Antibody 65

Pharmaceutical Technology

MARCH 2, 2023

QN-023a is under clinical development by Hangzhou Qihan Biotechnology and currently in Phase I for Relapsed Acute Myeloid Leukemia. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Gene Editing 100

Gene Editing Genetic Engineering Engineer Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Gastric Cancer. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is administered through intravenous drip route.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-2138 is under clinical development by Xencor and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Antibody 100

Antibody Engineer Clinical Trials Clinical Trials 100

The Pharma Data

DECEMBER 22, 2020

Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1. A2 anticipates that the successful development of its allogeneic Tmod candidate therapy will enable subsequently developed allogeneic Tmod candidates.

Development 52

Development Engineer Manufacturing In-Vitro 52

Pharmaceutical Technology

AUGUST 17, 2022

Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. These capabilities comprise cell and exosome genetic engineering for expressing therapeutic targets.

Manufacturing 130

Manufacturing Gene Therapy Genetic Engineering Gene 130

Pharmaceutical Technology

FEBRUARY 24, 2023

ACE-1334 is under clinical development by Merck and currently in Phase I for Lung Disease. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. It is developed based on protein engineering platform.

Production 100

Production Vaccination Vaccine Engineer 100

The Pharma Data

DECEMBER 13, 2020

Up to 1% of all solid tumors harbor NRG1 fusions, therefore, it is important to identify this patient population and develop therapies that can treat them. [1]. HMBD-001 is a uniquely differentiated anti-HER3 neutralizing antibody that was developed using Hummingbird’s proprietary Rational Antibody Discovery platform.

Clinical Development 52

Clinical Development Medicine Development Antibody 52

Pharmaceutical Technology

MARCH 2, 2023

Povetacicept is under clinical development by Alpine Immune Sciences and currently in Phase I for Systemic Lupus Erythematosus. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Protein 100

Protein Engineer Clinical Trials Clinical Trials 100

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Outsourcing Pharma

OCTOBER 20, 2023

Dave Hine is the senior director of sales and engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.

Life Science 79

Life Science Engineer Sales Clinical Development 79

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. “I Pfizer Inc. NYSE: PFE) today announced that Annaliesa Anderson, Ph.D.,

Vaccination 40

Vaccination Vaccine Development Research 40

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Drug Discovery World

DECEMBER 8, 2023

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. Both companies will share the costs of manufacturing and preclinical assessments.

Antibody 52

Antibody Gene Editing Clinical Trials Clinical Trials 52

XTalks

JUNE 23, 2022

Jason Bock is a biopharma industry veteran who helped build the Biologics Development team that was formerly part of the Therapeutics Discovery division at the University of Texas MD Anderson Cancer Center. Utilizing cellular therapies to fight cancer is an area of research and drug development that has been quickly advancing.

Manufacturing 98

Manufacturing Development Engineer Clinical Development 98

pharmaphorum

APRIL 19, 2022

T pioneer, Adrian Hayday, and together accelerate the development of effective, persistent, globally accessible cell therapy for solid tumors. Join the 3rd Gamma Delta T Therapies Summit to learn and network with 120+ of the world’s leaders including ??T The post 3rd Gamma Delta T Therapies Summit appeared first on.

Engineer 52

Engineer Clinical Development Manufacturing Production 52

pharmaphorum

SEPTEMBER 3, 2020

With AI the pharma industry hopes to reduce the number of drugs that fail during the clinical development process, a huge financial drain on the industry. The tech giant NVIDIA will also send a team of engineers to the building to explore ways of collaborating to discover new drugs.

Life Science 110

Life Science Engineer Scientist Pharma Companies 110

The Pharma Data

OCTOBER 26, 2020

This work complements the Company’s own development work currently being undertaken. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.” ” Market Abuse Regulation (MAR) Disclosure.

Development 40

Development Antibody Engineer Production 40

FDA Law Blog

JANUARY 4, 2023

Brevig, Senior Regulatory Device and Biologics Expert — On December 7, 2022, FDA’s Center for Biologics Evaluation and Research (CBER) and the Office of Tissues and Advanced Therapies (OTAT) held a town hall to answer questions related to cell therapy and tissue-engineered products chemistry, manufacturing, and contr­­ols (CMC).

Reagent 59

Reagent Manufacturing Production Gene Therapy 59

The Pharma Data

JULY 22, 2021

NYSE: PFE) today announced a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The companies will equally share worldwide development costs, commercialization expenses, and profits. Arvinas, Inc. Nasdaq: ARVN) and Pfizer Inc.

Protein 52

Protein Development HR Hormones 52

The Pharma Data

JANUARY 12, 2021

Working alongside KSQ will facilitate smart drug discovery and development of what we hope will be transformative new therapies for patients with intractable forms of cancer.”. In addition, KSQ will be eligible for additional option payments along with development and commercialization milestone payments. sales for that product.

Development 52

Development Research In-Vivo Genome 52

Drug Discovery World

APRIL 12, 2024

The Food and Drug Administration (FDA) has cautioned that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This latest approval means that Enhertu now has five approved indications, including for breast cancer. In DESTINY-Lung01, ORR of 52.9%

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

Pharmaceutical Technology

FEBRUARY 18, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Gevokizumab Overview Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

Drug Discovery World

JULY 3, 2023

This was centred around pre-clinical models (in vitro and in vivo) to support discovery and development, re-entering the fray with costimulatory agonists, and clinical development strategies for combinations with immune cell engagers​.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

FEBRUARY 12, 2024

Cameron Ross, SVP, Generative AI, Elsevier “AI has the potential to dramatically shorten one of the most costly areas of early drug development – small molecule discovery. The emergence of low-code and no-code software engineering will start to make CGT application development easier, enabling more rapid, innovative solutions.

Genome 139

Genome Genomics Life Science Gene Therapy 139

Pharmaceutical Technology

APRIL 5, 2023

This includes the first potential approval of a CRISPR-based gene therapy called exa-cel , which is developed by CRISPR Therapeutics and Vertex Pharmaceuticals. It’s a multifaceted issue and we perhaps need to go beyond our comfort zone in science and clinical development to understand what barriers patients are really facing.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

pharmaphorum

OCTOBER 5, 2022

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that targets muscle cells. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 103

RNA Genetics Dermatology Antibody 103

XTalks

SEPTEMBER 21, 2023

Since 2004, the NIAID has been championing the discovery and development of the cytomegalovirus (CMV) vector used to deliver the HIV vaccine material to the immune system without causing disease. These T cells are engineered to recognize various HIV proteins in a unique manner compared to previous experimental HIV vaccines.

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

OCTOBER 20, 2023

Intellia said NTLA-2001 is the first investigational in vivo CRISPR-based gene editing therapy cleared to enter late-stage clinical development. Intellia, which focuses on developing potentially curative therapies leveraging CRISPR-based technologies, plans to begin the Phase III trial for NTLA-2001 by the end of this year.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

Drug Discovery World

NOVEMBER 22, 2022

Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals. . ” . . The post Academic-industry collaboration extends cancer drug discovery alliance appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Research Engineer Medicine 52

Drug Discovery World

MAY 25, 2023

It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies. Astera Software: Astera API Management The new product is a no-code, automated, unified platform for complete API lifecycle management and integrations.

Production 52

Production Reagent DNA Drugs 52

The Pharma Data

NOVEMBER 22, 2020

Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase 3 cardiovascular outcomes clinical trial. Terms of Termination. GALACTIC-HF : Results and Next Steps.

Development 52

Development Clinical Trials Clinical Trials Trials 52

pharmaphorum

OCTOBER 21, 2022

Hookipa’s proprietary arenavirus platform is based on engineering arenaviruses to carry and deliver virus-specific or tumour-specific genes directly in patients in order to evoke an immune response by T cells, also known as CD8+ T cells.

Licensing 52

Licensing Licensing Immune Response Engineer 52

XTalks

MAY 9, 2024

We also invented four proprietary antibody technologies, including our DuoBody® bispecific technology which is the backbone of four FDA-approved bispecifics and over ten in development. What factors do you attribute to the company’s success in the discovery and development of differentiated antibody therapeutics?

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: In terms of developing antibodies directed against MHC, are there any manufacturing and engineering challenges?

Antibody 65

Antibody Protein Development Engineer 65